{"title":"Toward More Objective Measures in Psychiatry","authors":"J. P. Kelleher","doi":"10.4172/1522-4821.1000e387","DOIUrl":null,"url":null,"abstract":"The National Institute of Mental Health (NIMH) Director, Joshua A. Gordon, has emphasized the need for biomarkers in psychiatry (Gordon, 2018). A biomarker is an objective biological finding associated with a disease. The advantages of such indicators are obvious-a biomarker provides a clue to addressing underlying pathology. For example, in Alzheimer’s disease, beta amyloid plaques and tau neurofibrillary tangles constitute specific foci for research, and accumulation of these substances in asymptomatic individuals may have predictive value (National Institute of Health, 2018). Considering this, it is not surprising that Alzheimer’s disease is currently one of the leading neuroscience conditions for research investment (Sperling, et al., 2014). Other examples of biomarkers are found in depression, where one “Biotype” was recently associated with better response to transcranial magnetic stimulation (Drysdale, et al., 2017) and where the cingulate cortex was associated with a differential response to medication and psychotherapy (Dunlop, et al., 2017).","PeriodicalId":358022,"journal":{"name":"International Journal of Emergency Mental Health and Human Resilience","volume":"1 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2018-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Emergency Mental Health and Human Resilience","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/1522-4821.1000e387","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The National Institute of Mental Health (NIMH) Director, Joshua A. Gordon, has emphasized the need for biomarkers in psychiatry (Gordon, 2018). A biomarker is an objective biological finding associated with a disease. The advantages of such indicators are obvious-a biomarker provides a clue to addressing underlying pathology. For example, in Alzheimer’s disease, beta amyloid plaques and tau neurofibrillary tangles constitute specific foci for research, and accumulation of these substances in asymptomatic individuals may have predictive value (National Institute of Health, 2018). Considering this, it is not surprising that Alzheimer’s disease is currently one of the leading neuroscience conditions for research investment (Sperling, et al., 2014). Other examples of biomarkers are found in depression, where one “Biotype” was recently associated with better response to transcranial magnetic stimulation (Drysdale, et al., 2017) and where the cingulate cortex was associated with a differential response to medication and psychotherapy (Dunlop, et al., 2017).
美国国家精神卫生研究所(NIMH)主任约书亚·a·戈登(Joshua A. Gordon)强调了精神病学中生物标志物的必要性(Gordon, 2018)。生物标志物是与疾病相关的客观生物学发现。这些指标的优势是显而易见的——生物标志物提供了解决潜在病理的线索。例如，在阿尔茨海默病中，β淀粉样蛋白斑块和tau神经原纤维缠结是研究的特定焦点，这些物质在无症状个体中的积累可能具有预测价值(美国国立卫生研究院，2018)。考虑到这一点，阿尔茨海默病目前是研究投资的主要神经科学条件之一也就不足为奇了(Sperling, et al.， 2014)。在抑郁症中发现了其他生物标志物的例子，其中一种“生物型”最近与对经颅磁刺激的更好反应有关(Drysdale等人，2017)，扣带皮层与对药物和心理治疗的不同反应有关(Dunlop等人，2017)。
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
